The Levitronix CentriMag ventricular assist device as a bridge to decision in patients with end-stage heart failure: Our single-center experience

Rabuş, Murat Bülent

doi:10.5606/tgkdc.dergisi.2017.13843

Cited by 1 publication

(2 citation statements)

References 23 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Borisenko [1] reviewed 53 studies about VAD mean duration, survival rate, and complication rate, reported that the mean support day was 8 days, survival rate while on support was 62-83%, and the 30-day survival was 41-82.2%, depending on the placement indication. Furthermore, thrombosis and neurological complication rate was 7%, and device failure was observed in 0.08% of patients [5]. Therefore, patients without neurological deficit should quickly be bridged to either heart transplantation or implantation of a permanent VAD if cardiac grafts are unavailable [5].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, thrombosis and neurological complication rate was 7%, and device failure was observed in 0.08% of patients [5]. Therefore, patients without neurological deficit should quickly be bridged to either heart transplantation or implantation of a permanent VAD if cardiac grafts are unavailable [5]. Currently, the CentriMag system could be used as a bridge therapy to decision, particularly when patients undergo CPR or when the consciousness level is unclear, which is contraindicated for transplantation [6].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Huge thrombus formation in the left ventricle during bilateral CentriMag ventricular assist device with successful bridging to heart transplantation: a case report and review of the literature

2020

View full text Add to dashboard Cite

Owing to shortage of donor hearts, the ventricular assist device is used as a bridging therapy to heart transplantation. However, thrombus formation is a critical complication during ventricular assist device circulatory support that might result in ischemic infarction of end organs. Here, we report a patient diagnosed with decompensated dilated cardiomyopathy and cardiogenic shock who underwent emergent extracorporeal life support, and subsequent temporary bilateral ventricular assistance with the CentriMag device (Levitronix LLC, Waltham, MA). Daily transthoracic echocardiography did not detect any thrombus formation, and no stroke event occurred during biventricular support. During eventual orthotopic heart transplantation, transesophageal echocardiography detected a huge thrombus in the left ventricle. We removed the biventricular assist device, excised the recipient heart, cleaned up the thrombus, and then implanted the donor heart successfully. No stroke or transient neurological deficit was noted during or after the transplantation. The patient was discharged 14 days after transplantation. No major adverse cardiovascular event was noted during 2 years of outpatient follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%